SCHEMBL4480433

SCHEMBL4480433

CC(C)NC(=O)c1c[c]cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 2/20 0.37
ALOX5 P09917 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 2/20 0.36
LMNA P02545 1/20 0.36
MLYCD O95822 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
NPC1 O15118 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PRKCZ Q05513 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130977 0.75
SCHEMBL1905348 0.71
SCHEMBL11989148 0.70 HDAC3 (0.56) ALDH1A1TP53HPGDMAPK1ALOX5
SCHEMBL12376694 0.68 RAB9A (0.66) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL8593179 0.67 MLYCD (0.46) ALDH1A1HPGDALOX5LMNAMLYCD
SCHEMBL4488559 0.67 ALDH1A1 (0.41) ALDH1A1TP53HPGDMAPK1RAB9A
SCHEMBL24669892 0.67 ALDH1A1 (0.65) ALDH1A1TP53HPGDMAPK1RAB9A
SCHEMBL2614311 0.67 ACACB (0.52) ALDH1A1TP53HPGDMAPK1KMT2A
SCHEMBL13631431 0.67 DAO (0.55) ALDH1A1TP53HPGDMAPK1RAB9A
SCHEMBL163428 0.67 ALDH1A1 (0.45) ALDH1A1TP53HPGDMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 US claimed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 EP claimed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 US claimed
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 EP disclosed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063765-A1 Novel compounds CCR3, NSUN3, CCR1 ALDH1A1 2920/4885TP53 2716/4885HPGD 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.